Differential patterns of antibody response against SARS-CoV-2 nucleocapsid epitopes detected in sera from patients in the acute phase of COVID-19, convalescents, and pre-pandemic individuals
Pathogens and Disease · 2024
DOI: 10.1093/femspd/ftae025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens and Disease, 2024. Verfasst von Agnieszka Razim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, ul. Rudolfa Weigla 12, 53-114 Wro…. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Antibodies, Viral, Coronavirus Nucleocapsid Proteins. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Centre for Research and Development, Foundation for Polish Science.
Abstract (Originalsprache)
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more than 0.7 billion people and caused over 7 million deaths worldwide. At the same time, our knowledge about this virus is still incipient. In some cases, there is pre-pandemic immunity; however, its source is unknown. The analysis of patients’ humoral responses might shed light on this puzzle. In this paper, we evaluated the antibody recognition of nucleocapsid protein, one of the structural proteins of SARS-CoV-2. For this purpose, we used pre-pandemic acute COVID-19 and convalescent patients’ sera to identify and map nucleocapsid protein epitopes. We identified a common epitope KKSAAEASKKPRQKRTATKA recognized by sera antibodies from all three groups. Some motifs of this sequence are widespread among various coronaviruses, plants or human proteins indicating that there might be more sources of nucleocapsid-reactive antibodies than previous infections with seasonal coronavirus. The two sequences MSDNGPQNQRNAPRITFGGP and KADETQALPQRQKKQQTVTL were detected as specific for sera from patients in the acute phase of infection and convalescents making them suitable for future development of vaccines against SARS-CoV-2. Knowledge of the humoral response to SARS-CoV-2 infection is essential for the design of appropriate diagnostic tools and vaccine antigens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, ul. Rudolfa Weigla 12, 53-114 Wrocław, Poland.
- Department of Infectious Diseases, Liver Diseases and Acquired Immune Deficiencies, Wroclaw Medical University, Wybrzeże L. Pasteura 1, 50-367 Wrocław, Poland.
- Department of Immunology of Infectious Diseases, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, ul. Rudolfa Weigla 12, 53-114 Wrocław, Poland.
ORCID-Profile: Agnieszka Razim, Katarzyna Pacyga-Prus, Wioletta Kazana-Płuszka, Agnieszka Zabłocka, Józefa Macała, Hubert Ciepłucha, Andrzej Gamian, Sabina Górska
Förderung
- National Centre for Research and Development
- Foundation for Polish Science
Zitieren
APA
Razim, A., Pacyga-Prus, K., Kazana-Płuszka, W., Zabłocka, A., Macała, J., Ciepłucha, H., Gamian, A., & Górska, S. (2024). Differential patterns of antibody response against SARS-CoV-2 nucleocapsid epitopes detected in sera from patients in the acute phase of COVID-19, convalescents, and pre-pandemic individuals. Pathogens and Disease. https://doi.org/10.1093/femspd/ftae025
Vancouver
Razim A, Pacyga-Prus K, Kazana-Płuszka W, Zabłocka A, Macała J, Ciepłucha H, et al. Differential patterns of antibody response against SARS-CoV-2 nucleocapsid epitopes detected in sera from patients in the acute phase of COVID-19, convalescents, and pre-pandemic individuals. Pathogens and Disease. 2024. doi:10.1093/femspd/ftae025
BibTeX
@article{Razim2024,
author = {Razim, Agnieszka and Pacyga-Prus, Katarzyna and Kazana-Płuszka, Wioletta and Zabłocka, Agnieszka and Macała, Józefa and Ciepłucha, Hubert and Gamian, Andrzej and Górska, Sabina},
title = {Differential patterns of antibody response against SARS-CoV-2 nucleocapsid epitopes detected in sera from patients in the acute phase of COVID-19, convalescents, and pre-pandemic individuals},
journal = {Pathogens and Disease},
year = {2024},
doi = {10.1093/femspd/ftae025}
}
EUVIMED